StreetInsider.com News Articles

Form 425 Werewolf Therapeutics, Filed by: Werewolf Therapeutics, Inc.

Fri, 21 Aug 2026 09:13:00 -0400

si-local-file:///var/storage/secattach/20260821/26959007.html

Form 425 Werewolf Therapeutics, Filed by: Werewolf Therapeutics, Inc.

Fri, 21 Aug 2026 09:13:00 -0400

si-local-file:///var/storage/secattach/20260821/26959007.html

Form 8-K Werewolf Therapeutics, For: Aug 21

Fri, 21 Aug 2026 09:11:00 -0400

si-local-file:///var/storage/secattach/20260821/26958985.html

Form 8-K Werewolf Therapeutics, For: Aug 21

Fri, 21 Aug 2026 09:11:00 -0400

si-local-file:///var/storage/secattach/20260821/26958985.html

Werewolf Therapeutics to merge with Ambros in $150M private placement

Fri, 21 Aug 2026 08:00:17 -0400

Werewolf Therapeutics (Nasdaq: HOWL) and Ambros Therapeutics announced a definitive all-stock merger agreement, accompanied by a $150 million oversubscribed private placement, according to a press release issued Aug. 21, 2026.

The combined company will operate under the Ambros Therapeutics name, headquartered in San Diego, and is expected to trade on Nasdaq under the ticker "AMBX." The transaction is expected to close by the first quarter of 2027, pending stockholder approvals and other customary closing conditions.

The merger values Ambros Therapeutics at $500 million and Werewolf Therapeutics at $47.5 million before the concurrent private placement. Upon closing, pre-merger Ambros stockholders are expected to

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement

Fri, 21 Aug 2026 08:00:00 -0400

Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly diagnosed U.S. patients annually and no currently FDA-approved therapy
Pivotal CRPS-RISE Phase 3 trial evaluating neridronate remains ongoing, with FDA Breakthrough Therapy, Fast Track and Orphan Drug designations received and alignment with FDA that a single successful pivotal trial could potentially support approval
Neridronate has been administered to approximately 600,000 patients in Italy across approved indications including CRPS-1
Concurrent oversubscribed private placement of $150 million from a syndicate of

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent Oversubscribed $150 million Private Placement

Fri, 21 Aug 2026 08:00:00 -0400

Proposed merger to create a Nasdaq-listed, late-stage biotechnology company advancing neridronate, a potential first FDA-approved treatment for CRPS-1, a debilitating orphan disease with 65,000 newly diagnosed U.S. patients annually and no currently FDA-approved therapy
Pivotal CRPS-RISE Phase 3 trial evaluating neridronate remains ongoing, with FDA Breakthrough Therapy, Fast Track and Orphan Drug designations received and alignment with FDA that a single successful pivotal trial could potentially support approval
Neridronate has been administered to approximately 600,000 patients in Italy across approved indications including CRPS-1
Concurrent oversubscribed private placement of $150 million from a syndicate of

Werewolf Therapeutics sells platform assets to EMD Serono for $33M

Thu, 20 Aug 2026 16:12:31 -0400

Werewolf Therapeutics (NASDAQ: HOWL) sold its pre-clinical INDUCER platform and portions of its INDUKINE platform to EMD Serono Research & Development Institute Inc. on Aug. 14, 2026, under an asset purchase agreement.

Under the terms of the agreement, EMD Serono agreed to pay $28.0 million upfront, with an additional $5.0 million due upon completion of the technology transfer, bringing the total potential consideration to $33.0 million.

The transferred assets include all patents and know-how related to the INDUCER platform, pre-clinical compounds and related intangible assets, as well as certain patents and know-how from the INDUKINE platform. Werewolf retains all rights necessary for

Werewolf Therapeutics sells platform assets to EMD Serono for $33M

Thu, 20 Aug 2026 16:12:31 -0400

Form 8-K Werewolf Therapeutics, For: Aug 14

Thu, 20 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260820/26956195.html

Form 8-K Werewolf Therapeutics, For: Aug 14

Thu, 20 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260820/26956195.html

Werewolf Therapeutics, Inc. (HOWL) Tops Q2 EPS by 36c

Fri, 31 Jul 2026 07:14:05 -0400

Werewolf Therapeutics, Inc. (NASDAQ: HOWL) reported Q2 EPS of $0.08, $0.36 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $21 million.

For earnings history and earnings-related data on Werewolf Therapeutics, Inc. (HOWL) click here.

Form 10-Q Werewolf Therapeutics, For: Jun 30

Fri, 31 Jul 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20260731/26846666.html

Form 10-Q Werewolf Therapeutics, For: Jun 30

Fri, 31 Jul 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20260731/26846666.html

Form 8-K Werewolf Therapeutics, For: Jul 31

Fri, 31 Jul 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260731/26846629.html

Form 8-K Werewolf Therapeutics, For: Jul 31

Fri, 31 Jul 2026 07:06:00 -0400

si-local-file:///var/storage/secattach/20260731/26846629.html

Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Updates